Journal article
Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials.
- Abstract:
-
Objectives
Expand abstract
To investigate the safety of ofatumumab retreatment in rheumatoid arthritis.
Methods
Patients with active rheumatoid arthritis participating in two phase III trials (OFA110635 and OFA110634) and a phase II extension trial (OFA111752) received individualised open-label ofatumumab retreatment (700 mg X 2 intravenous infusions two weeks apart) ≥24 weeks following the first course and ≥16 weeks following further courses. Retreatment required evidence of clinical ...
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Authors
Funding
GlaxoSmithKline Pharmaceuticals
More from this funder
Genmab
More from this funder
Bibliographic Details
- Publisher:
- Public Library of Science Publisher's website
- Journal:
- PLoS One Journal website
- Volume:
- 11
- Issue:
- 6
- Pages:
- 320-330
- Publication date:
- 2016-06-23
- Acceptance date:
- 2016-06-05
- DOI:
- EISSN:
-
1932-6203
- ISSN:
-
1932-6203
- Source identifiers:
-
656055
Item Description
- Keywords:
- Pubs id:
-
pubs:656055
- UUID:
-
uuid:b767952c-880b-49f3-8dc3-5c8caea843fa
- Local pid:
- pubs:656055
- Deposit date:
- 2016-11-01
Terms of use
- Copyright holder:
- Quattrocchi et al
- Copyright date:
- 2016
- Notes:
- © 2016 Quattrocchi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License.
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record